Dr Emilia Molimpakis is a neuroscientist-turned-co-founder of the healthtech platform Thymia: A diagnostics platform that can be used by clinicians and patients to accurately assess and monitor depression. Inspired by video games, it uses neuropsychology and linguistics to pick up on subtle markers of depression that might otherwise be missed. The platform secured a pre-seed raise of $1.1m US dollars earlier in 2022, and is expanding rapidly to support clinicians and patients across the UK, Europe, and the US. Emilia has a PhD in Neurolinguistics, and prior to co-founding Thymia, she worked for over a decade as a researcher using language as biomarker for cognitive decline and treatment response in neurological disease patient populations. We talk today about being on the startup treadmill and finding your perfect co-founder; moving from the theoretical in academia to building a product in the real world; and the role of video games in patient care. You can find out more about Thymia in the following ways: https://thymia.ai/ info@thymia.ai LinkedIn: https://www.linkedin.com/company/thymia Find us on: www.founders-keepers.com Instagram: @founderskeepers.pod Twitter: @founders_pod LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast Get in touch: hi@founders-keepers.com